Table 3. Differences in pulmonary function before and after R-2-CdA therapy.
| Pulmonary function index | Patient 1 | Patient 2 | Patient 3 | |||||
|---|---|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |||
| FVC (L) | 3.15 | 3.13 | 2.45 | 2.75 | 2.92 | 3.23 | ||
| FVC (%) | 75.03 | 73.52 | 81.83 | 80.43 | 67.32 | 77.33 | ||
| TLC (L) | 4.57 | 4.84 | NT | 4.04 | 3.52 | 4.63 | ||
| TLC (%) | 74.49 | 85.79 | NT | 80.41 | 57.66 | 75.83 | ||
| DLCO (mL·mmHg-1·min-1) | 10.63 | 12.54 | NT | 14.92 | 21.78 | 23.98 | ||
| DLCO (%) | 44.34 | 51.71 | NT | 76.41 | 85.00 | 96.94 | ||
| FEV1 (L) | 2.21 | 2.03 | 2.11 | 2.26 | 2.25 | 2.35 | ||
| FEV1 (%) | 65.27 | 62.08 | 87.3 | 83.74 | 65.45 | 70.53 | ||
| PaO2 (mmHg) | 76 | 82 | 72 | 83 | 72 | 82 | ||
FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity of carbon monoxide; FEV1, forced expiratory volume in 1 second; PaO2, arterial partial pressure of oxygen; NT, not tested; significant improvement was highlighted in bold.